Filgotinib Bows Out of the RA Race in the USA--Gilead Sciences Inc announced yesterday that it has decided not to pursue the rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca). https://t.co/XAR3T8AQpR https://t.co/GlQB9L8Jnd